1-Dimethylaminomethyl-LSD

1-Dimethylaminomethyl-LSD
Clinical data
Other names	1-Dimethylaminomethyl-N,N-diethyllysergamide; 1-[(Dimethylamino)methyl]-N,N-diethyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
ATC code	None;
Identifiers
	IUPAC name (6aR,9R)-4-[(dimethylamino)methyl]-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
Chemical and physical data
Formula	C23H32N4O
Molar mass	380.536 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3CN(C)C)CC;
	InChI InChI=1S/C23H32N4O/c1-6-26(7-2)23(28)17-11-19-18-9-8-10-20-22(18)16(12-21(19)25(5)13-17)14-27(20)15-24(3)4/h8-11,14,17,21H,6-7,12-13,15H2,1-5H3/t17-,21-/m1/s1; Key:NSFZERINUKJKQV-DYESRHJHSA-N;

1-Dimethylaminomethyl-LSD is a lysergamide derivative related to the psychedelic drug lysergic acid diethylamide (LSD).^[1]^[2]^[3]^[4]^[5] It was synthesized and described by Albert Hofmann and Franz Troxler at Sandoz in 1957.^[1]^[3]^[4]^[5] According to Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), 1-dimethylaminomethyl-LSD has been limitedly described, and it is unknown whether it was ever tested in humans.^[1] The 2-dimethylaminomethyl-LSD positional isomer has also been described, and was found to have 18.5% of the antiserotonergic activity of LSD in vitro.^[6]

Quick facts Clinical data, Other names ...

See also